Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTVandita JadejaSat, July 4, 2026 at 8:00 PM GMT+2 4 min readQuick ReadMounjaro and Zepbound drove Lilly's revenue up 56% while JNJ grew 10% and extended its dividend streak to 64 consecutive years.Lilly partnered with NVIDIA on a drug-discovery lab and committed $6 billion to a new Alabama plant to scale its GLP-1 pipeline.Lilly's 33x forward P/E reflects concentrated GLP-1 risk, while JNJ's 22x valuation and low beta make it the steadier income play.Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.Eli Lilly (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks for winning in healthcare. Lilly is riding a GLP-1 wave. JNJ is proving that a wide, refreshed portfolio can still compound. Both raised guidance and both are worth putting side by side right now.Michael Ciaglo / Getty Images News via Getty ImagesGLP-1 Fireworks vs. a Deep BenchLilly posted $19.80 billion in revenue, up 55.5% year over year, with Mounjaro alone contributing $8.66 billion and Zepbound adding $4.16 billion. That is a staggering concentration in metabolic drugs, and it delivered non-GAAP EPS of $8.55.CEO David Ricks said "2026 is off to a strong start", spotlighting the FDA approval of Foundayo, the first oral GLP-1 pill without food or water restrictions.JNJ told a very different story. Revenue of $24.062 billion grew 9.9%, split between Innovative Medicine at $15.426 billion and MedTech at $8.636 billion. DARZALEX cleared $3.964 billion, TREMFYA jumped 68.3%, and cardiovascular MedTech rose 13% on Abiomed and Shockwave strength.CEO Duato called the portfolio "unrivaled", pointing to ICOTYDE, the first targeted oral peptide for plaque psoriasis.Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.Business DriverEli LillyJohnson & JohnsonMain growth engineMounjaro + Zepbound (GLP-1)Oncology + immunology switch to TREMFYABiggest drag13% price decline on rebatesSTELARA down 59.7% from biosimilarsQ1 revenue growth55.5%9.9%One Company Concentrates, the Other DiversifiesLilly is doubling down on metabolic dominance. Ricks highlighted acquisitions of Orna, Centessa, Kelonia, and Ajax, plus a $6 billion Alabama plant and an NVIDIA (NASDAQ:NVDA) drug-discovery lab. Guidance now sits at $82 to $85 billion in revenue and $35.50 to $37 EPS. The trailing P/E of 42 reflects that ambition, and the stock is up 56.86% over the past year.JNJ is sharpening focus by spinning off DePuy Synthes orthopaedics within 18 to 24 months. Full-year guidance climbed to $100.3 to $101.3 billion with adjusted EPS of $11.45 to $11.65. The dividend rose 3.1% to $1.34, marking 64 consecutive years of increases. Forward P/E of 22 and beta of 0.256 flag it as the calmer name.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info